Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 29, Issue 1, Pages 35-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2019.08.003
Keywords
Basket trial; Bucket trial; Master protocol; Cancer drug development; Precision oncology
Funding
- ZIA [BC 011078]
- National Cancer Institute (JHD)
- ASCO Young Investigator Award (DBD)
Ask authors/readers for more resources
Progress toward the implementation of a molecular characterization paradigm in cancer drug development over the past 20 years has markedly enhanced our capability to select patients who are more likely to benefit from cancer therapy. Improvements in genomic and related diagnostic testing platforms have permitted evaluation of the efficacy of treatment assignment based on predefined biologic features of a patient's tumor or germline using master protocols that may include many malignancies and their molecularly characterized subsets. With this approach, a wide range of new targeted and immunologic treatment approaches have been defined for patients who, heretofore, lacked effective therapeutic options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available